All In Biotech

Drug Trial Radar · NCT00075998

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 826 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

826

Actual

Start

Dec 2003

Primary completion

Not stated

Study completion May 2007

Sponsor

Lead sponsor
InterMuneIndustry
Sponsor type
Industry
First posted
Jan 14, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe * Randomization: 2:1 active-to-placebo ratio * Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)

Conditions

  • Idiopathic Pulmonary Fibrosis
  • Lung Disease
  • Pulmonary Fibrosis

Interventions

  • Interferon gamma-1b ("Actimmune")Drug

    200 mcg, SQ, 3x per week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival time from randomization to treatment completion visit, or, end of treatment period, or, last known vital status.Time frame: 3.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • InterMune, Inc.

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.